Identifying Children With Leukemia Predisposition Syndromes

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.

In this video, Sharon A. Savage, MD, of the National Institutes of Health in Bethesda, Maryland, reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.

Savage gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content
Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Roman Fabbricatore
January 10th 2025
Article
A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

New Developments in CAR T Treatments Webinar Series Summary

New Developments in CAR T Treatments Webinar Series Summary

American Society for Transplantation and Cellular Therapy
December 24th 2024
Article

The "New Developments in CAR T Treatments" webinar series brought together leading experts in the field of cancer immunotherapy to discuss the latest advancements and ongoing research in CAR T and natural killer cell therapies.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia

NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia

Tim Cortese
December 19th 2024
Article

Results from a phase 1a trial showed that NX-5948 yielded an overall response rate of 77.8% in later lines of treatment for patients with WM.

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.

FDA Approves Remestemcel-L in Pediatric SR-aGVHD

Russ Conroy
December 18th 2024
Article

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.